NASDAQ : TELO
Telomir Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.9352 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 68.85M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 68.85M |
| Enterprise Value | 63.81M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 73.62M |
| Shares Outstanding | 73.62M |
| Shares Change (YoY) | +34.76% |
| Shares Change (QoQ) | +76.95% |
| Owned by Insiders (%) | 19.26% |
| Owned by Institutions (%) | 4.01% |
| Float | 41.98M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 12.78 |
| P/TBV Ratio | 13.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.14 |
| Quick Ratio | 15.55 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,102.65 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -213.10% |
| Return on Assets (ROA) | -122.81% |
| Return on Invested Capital (ROIC) | -132.44% |
| Return on Capital Employed (ROCE) | -120.93% |
| Weighted Average Cost of Capital (WACC) | 2.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.30 |
| 52-Week Price Change | -37.65% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 1.22 |
| Relative Strength Index (RSI) | 29.36 |
| Average Volume (20 Days) | 134,101 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 769,992 |
| Short Previous Month | 825,678 |
| Short % of Shares Out | 1.05% |
| Short % of Float | 1.83% |
| Short Ratio (days to cover) | 5.45 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.09M |
| Pretax Income | -5.88M |
| Net Income | -51.99M |
| EBITDA | n/a |
| EBIT | -6.09M |
| Earnings Per Share (EPS) | -$1.29 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.17M |
| Total Debt | 136,898 |
| Net Cash | 5.03M |
| Net Cash Per Share | $0.07 |
| Equity (Book Value) | 5.03M |
| Book Value Per Share | 0.07 |
| Working Capital | 5.03M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -4.91M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 136,373 |
| Free Cash Flow | -6.47M |
| FCF Per Share | -$0.09 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -34.76% |
| Shareholder Yield | -34.76% |
| Earnings Yield | -137.74% |
| FCF Yield | -9.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |